ARTICLE | Clinical News
IBPI completes Protegrin Phase III enrollment
January 16, 2001 8:00 AM UTC
IntraBiotics (IBPI) completed enrollment in a Phase III study of its Protegrin IB-367 synthetic antimicrobial peptide analog rinse to treat ulcerative oral mucositis in chemotherapy patients. The comp...